VincentThe LucMaMD

Oncology • Madison, WI

Melanoma

University of Wisconsin Carbone Cancer Center

Join to view full profile

Dr. Ma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ma's full profile

Already have an account?

Office
600 Highland Ave
Madison, WI 53792
Phone+1 608-265-1700

Fax+1 608-266-6020

Summary

Dr. Vincent Ma is an oncologist in Madison, WI and is affiliated with University of Wisconsin Carbone Cancer Center. He specializes in melanoma and is experienced in basal cell carcinoma, uveal melanoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma. He has more than 20 publications and over 250 citings.

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2018 - 2021
University of MichiganResidency, Internal Medicine, 2015 - 2018
University of MichiganInternship, Internal Medicine, 2015 - 2016
University of Nevada, Reno School of MedicineClass of 2015, MD
University of Nevada, RenoBS, Biochemistry & Molecular Biology, Summa Cum Laude, 2008 - 2011

Certifications & Licensure

WI State Medical License 2021 - 2025
MI State Medical License 2015 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 Start of enrollment: 2022 Nov 17
Recruiting
Phase 1
Roles: Contact
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients Start of enrollment: 2024 Jan 30
Recruiting
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) Start of enrollment: 2023 Jun 23
Recruiting
Phase 2
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors Start of enrollment: 2022 Dec 08
Recruiting
Phase 1, Phase 2
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies Start of enrollment: 2019 Oct 30
Recruiting
Phase 1
MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma Start of enrollment: 2023 Jun 01
Recruiting
Phase 1, Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Start of enrollment: 2022 Aug 11
Recruiting
Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Start of enrollment: 2021 Jan 06
Recruiting
Phase 2
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
Recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.
Allison L Gradone, Vincent T Ma, Alexi Vasbinder, Leslie A Fecher, Sarah Yentz
Cancer Immunology, Immunotherapy. 2024-10-05
Successful Treatment of Metastatic Primary Cutaneous Adnexal Carcinoma With a PD-1 Inhibitor.
Janmesh D Patel, Vincent J Pozorski, Nika Tavberidze, Darya G Buehler, Wei Huang
Journal of Immunotherapy. 2024-10-01
1 citations
Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma.
Christopher D Lao, James Moon, Vincent T Ma, John P Fruehauf, Lawrence E Flaherty
Cancer. 2024-09-29